Session Details
[D3-A3]Bioanalytical Strategy in Biopharmaceutical Development
Fri. Mar 6, 2026 3:05 PM - 3:55 PM JST
Fri. Mar 6, 2026 6:05 AM - 6:55 AM UTC
Fri. Mar 6, 2026 6:05 AM - 6:55 AM UTC
Medium Hall(2nd Floor)
Chairman:Masanori Nagata(Astellas Pharma Inc.), Takashi Miyayama(Chugai Pharmaceutical Co., Ltd.)
[D3-A3-01]Bioanalysis in Dual-Payload ADC: Case Study of Analytical Strategy and Quantitation of total antibody and ADCs by IA-LC/MS/MS
*Yuji Fujita1, Toshihiro Matsuda1, Guifen Xu2, Werner Rubas2 (1. Astellas Pharma Inc., 2. Sutro Biopharma Inc.)
[D3-A3-02]Strategies for Selecting Critical Reagents and Developing Analytical Methods Based on Antibody and Target Characteristics in Antibody Therapeutics Development
*Ken Ohmine1 (1. Pharmaceutical Science Dept., Chugai Pharmaceutical Co., Ltd.)